On May 15, the Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 9996. HK)

The Company received a confirmation letter from the National Medical Products Administration of the People’s Republic of China confirming its acceptance of the registration application for TaurusOne®

The Company successfully completed staged animal experimentation for mitral valve edge-to-edge repair.

The Company signed a license and technology transfer agreement with HighLife for transseptal mitral valve replacement products.

The Company obtained NMPA's approval for SacSpeed® and Tethys®.

The Company obtained the Contract Manufacturing License to manufacture under the Jiangsu Pilot Marketing Authorization Holder (MAH) System.

The Company was formally incorporated into the Hang Seng Composite Index and was listed on the Hong Kong Stock Connect.